{"id":9791,"date":"2025-03-11T12:34:08","date_gmt":"2025-03-11T19:34:08","guid":{"rendered":"https:\/\/www.breakthrought1d.org\/pacificnorthwest\/?p=9791"},"modified":"2026-05-21T19:46:29","modified_gmt":"2026-05-21T19:46:29","slug":"clinical-trials-highlight-sugarnsalt-trial","status":"publish","type":"post","link":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/","title":{"rendered":"CLINICAL TRIALS HIGHLIGHT \u2013 SUGARNSALT TRIAL"},"content":{"rendered":"<p>Are You Interested in Participating in a Research Study at OHSU to Determine if Sotagliflozin can Help Slow Kidney Function Decline in People with Type 1 Diabetes?<\/p>\n<p>The SugarNSalt Trial, is currently enrolling participants with <a href=\"https:\/\/www.breakthrought1d.org\/t1d-basics\/\">Type 1 Diabetes<\/a> and moderate to severe <a href=\"https:\/\/www.breakthrought1d.org\/t1d-resources\/complications\/kidney-disease\/\">diabetic kidney disease<\/a> at Oregon Health and Science University (OHSU) under the direction of site physician Dr. Rodica Busui. This trial is determining if an investigational oral medication called Sotagliflozin (SOTA) can help slow kidney function decline in patients with type 1 diabetes. This trial is being funded by <a href=\"https:\/\/www.breakthrought1d.org\/\">Breakthrough T1D<\/a> and will act as an aid in determining future treatments and improving quality of life for patients with diabetic kidney disease.<\/p>\n<p>SOTA is a drug in the family of medications called SGLT1 and SGLT2 (sodium\/glucose transport) inhibitors and is currently approved by the FDA to reduce the risk of being admitted to the hospital due to heart failure in persons with type 2 diabetes and other conditions. Some studies have shown that drugs like SOTA may also slow the progression of kidney disease in people with and without diabetes.<\/p>\n<h2>THE STUDY<\/h2>\n<h3>Aim<\/h3>\n<p>The goal of this study is to determine whether SOTA can help slow the progression of kidney function decline in people with type 1 diabetes.<\/p>\n<h3>Inclusion Criteria<\/h3>\n<p>You may be eligible to participate if you are:<\/p>\n<ul>\n<li>Diagnosed with type 1 diabetes for at least 8 years and continuously treated with insulin<\/li>\n<li>Between the ages of 18 and 75 years<\/li>\n<li>Have been told by your doctor that you have diabetic kidney disease or protein in your urine<\/li>\n<\/ul>\n<h3>What Is Involved?<\/h3>\n<ul>\n<li>The study consists of 18 clinic visits and 1 phone visit over 3 years.<\/li>\n<li>You will be randomized to take SOTA or an inactive pill that looks like SOTA once daily for the duration of the study.<\/li>\n<li>Study visits include blood and urine sampling, medical history review, physical exam and ECG, and surveys.<\/li>\n<li>Participants will continuously wear a Continuous Glucose Monitoring (CGM) device and periodically measure blood ketones by finger sticks.<\/li>\n<li>Participants will receive $50 per study visit except for one virtual visit.<\/li>\n<\/ul>\n<h3>Contact Information<\/h3>\n<p>To discuss this study or find out if you\u2019re eligible, please contact OSHU study staff (Aly Carlson or Krista Metas) by phone or email.<\/p>\n<p><strong>Oregon Health and Science University | Portland, Oregon<\/strong><\/p>\n<p>Aly Carlson: 971-610-3005<br \/>\nKrista Metas: 971-484-5758<br \/>\nEmail: <a href=\"mailto:sugarnsalt@ohsu.edu\">sugarnsalt@ohsu.edu<\/a><br \/>\nOHSU IRB#: 27158<\/p>\n<p>University of Washington is an additional site for this study. If you live closer to Seattle and are interested in this study, please contact Paul Ly,\u00a0<a title=\"mailto:lypaul@uw.edu\" href=\"mailto:lypaul@uw.edu\" data-linkindex=\"0\">lypaul@uw.edu<\/a>, (206) 685-2007.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Are You Interested in Participating in a Research Study at OHSU to Determine if Sotagliflozin can Help Slow Kidney Function Decline in People with Type 1 Diabetes? The SugarNSalt Trial, is currently enrolling participants with Type 1 Diabetes and moderate&hellip;<\/p>\n","protected":false},"author":1317,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"ep_exclude_from_search":false,"publish_on_app_meta":"True","iawp_total_views":88,"footnotes":"","_members_access_role":[],"_members_access_error":"","bt1d_storytelling_post":false,"bt1d_storytelling_more_posts":[]},"topics":[31,16],"class_list":["post-9791","post","type-post","status-publish","format-standard","hentry","jdrf_topic-clinical-trials","jdrf_topic-research"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SugarNSalt T1D Study at OHSU | Breakthrough T1D Greater Northwest<\/title>\n<meta name=\"description\" content=\"Fight back against diabetic kidney disease. The Breakthrough T1D-funded SugarNSalt trial is actively seeking volunteers in Washington and Oregon to test if oral sotagliflozin can shield renal health.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SugarNSalt T1D Study at OHSU | Breakthrough T1D Greater Northwest\" \/>\n<meta property=\"og:description\" content=\"Fight back against diabetic kidney disease. The Breakthrough T1D-funded SugarNSalt trial is actively seeking volunteers in Washington and Oregon to test if oral sotagliflozin can shield renal health.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Northwest Chapter\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/breakthrought1dHQ\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-11T19:34:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-21T19:46:29+00:00\" \/>\n<meta name=\"author\" content=\"Breakthrough T1D Author\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@breakthrought1d\" \/>\n<meta name=\"twitter:site\" content=\"@breakthrought1d\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Breakthrough T1D Author\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2025\\\/03\\\/11\\\/clinical-trials-highlight-sugarnsalt-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2025\\\/03\\\/11\\\/clinical-trials-highlight-sugarnsalt-trial\\\/\"},\"author\":{\"name\":\"Breakthrough T1D Author\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#\\\/schema\\\/person\\\/d91bebaf8f6259d18f7a0d24d101e6e6\"},\"headline\":\"CLINICAL TRIALS HIGHLIGHT \u2013 SUGARNSALT TRIAL\",\"datePublished\":\"2025-03-11T19:34:08+00:00\",\"dateModified\":\"2026-05-21T19:46:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2025\\\/03\\\/11\\\/clinical-trials-highlight-sugarnsalt-trial\\\/\"},\"wordCount\":419,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2025\\\/03\\\/11\\\/clinical-trials-highlight-sugarnsalt-trial\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2025\\\/03\\\/11\\\/clinical-trials-highlight-sugarnsalt-trial\\\/\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2025\\\/03\\\/11\\\/clinical-trials-highlight-sugarnsalt-trial\\\/\",\"name\":\"SugarNSalt T1D Study at OHSU | Breakthrough T1D Greater Northwest\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#website\"},\"datePublished\":\"2025-03-11T19:34:08+00:00\",\"dateModified\":\"2026-05-21T19:46:29+00:00\",\"description\":\"Fight back against diabetic kidney disease. The Breakthrough T1D-funded SugarNSalt trial is actively seeking volunteers in Washington and Oregon to test if oral sotagliflozin can shield renal health.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2025\\\/03\\\/11\\\/clinical-trials-highlight-sugarnsalt-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2025\\\/03\\\/11\\\/clinical-trials-highlight-sugarnsalt-trial\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/2025\\\/03\\\/11\\\/clinical-trials-highlight-sugarnsalt-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CLINICAL TRIALS HIGHLIGHT \u2013 SUGARNSALT TRIAL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#website\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/\",\"name\":\"Greater Northwest Chapter\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/BT1D-favi.png\",\"contentUrl\":\"https:\\\/\\\/www.breakthrought1d.org\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/BT1D-favi.png\",\"width\":400,\"height\":400,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/breakthrought1dHQ\",\"https:\\\/\\\/x.com\\\/breakthrought1d\",\"https:\\\/\\\/www.youtube.com\\\/@breakthrought1d\",\"https:\\\/\\\/www.instagram.com\\\/breakthrought1d\\\/\",\"https:\\\/\\\/www.tiktok.com\\\/@breakthrought1dhq\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/greaternorthwest\\\/#\\\/schema\\\/person\\\/d91bebaf8f6259d18f7a0d24d101e6e6\",\"name\":\"Breakthrough T1D Author\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"caption\":\"Breakthrough T1D Author\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SugarNSalt T1D Study at OHSU | Breakthrough T1D Greater Northwest","description":"Fight back against diabetic kidney disease. The Breakthrough T1D-funded SugarNSalt trial is actively seeking volunteers in Washington and Oregon to test if oral sotagliflozin can shield renal health.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/","og_locale":"en_US","og_type":"article","og_title":"SugarNSalt T1D Study at OHSU | Breakthrough T1D Greater Northwest","og_description":"Fight back against diabetic kidney disease. The Breakthrough T1D-funded SugarNSalt trial is actively seeking volunteers in Washington and Oregon to test if oral sotagliflozin can shield renal health.","og_url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/","og_site_name":"Greater Northwest Chapter","article_publisher":"https:\/\/www.facebook.com\/breakthrought1dHQ","article_published_time":"2025-03-11T19:34:08+00:00","article_modified_time":"2026-05-21T19:46:29+00:00","author":"Breakthrough T1D Author","twitter_card":"summary_large_image","twitter_creator":"@breakthrought1d","twitter_site":"@breakthrought1d","twitter_misc":{"Written by":"Breakthrough T1D Author","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/#article","isPartOf":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/"},"author":{"name":"Breakthrough T1D Author","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6"},"headline":"CLINICAL TRIALS HIGHLIGHT \u2013 SUGARNSALT TRIAL","datePublished":"2025-03-11T19:34:08+00:00","dateModified":"2026-05-21T19:46:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/"},"wordCount":419,"commentCount":0,"publisher":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/","url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/","name":"SugarNSalt T1D Study at OHSU | Breakthrough T1D Greater Northwest","isPartOf":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#website"},"datePublished":"2025-03-11T19:34:08+00:00","dateModified":"2026-05-21T19:46:29+00:00","description":"Fight back against diabetic kidney disease. The Breakthrough T1D-funded SugarNSalt trial is actively seeking volunteers in Washington and Oregon to test if oral sotagliflozin can shield renal health.","breadcrumb":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/2025\/03\/11\/clinical-trials-highlight-sugarnsalt-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/"},{"@type":"ListItem","position":2,"name":"CLINICAL TRIALS HIGHLIGHT \u2013 SUGARNSALT TRIAL"}]},{"@type":"WebSite","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#website","url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/","name":"Greater Northwest Chapter","description":"","publisher":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#organization","name":"Breakthrough T1D","url":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/logo\/image\/","url":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","contentUrl":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","width":400,"height":400,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/breakthrought1dHQ","https:\/\/x.com\/breakthrought1d","https:\/\/www.youtube.com\/@breakthrought1d","https:\/\/www.instagram.com\/breakthrought1d\/","https:\/\/www.tiktok.com\/@breakthrought1dhq"]},{"@type":"Person","@id":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6","name":"Breakthrough T1D Author","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","caption":"Breakthrough T1D Author"}}]}},"_links":{"self":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/posts\/9791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/users\/1317"}],"replies":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/comments?post=9791"}],"version-history":[{"count":0,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/posts\/9791\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/media?parent=9791"}],"wp:term":[{"taxonomy":"jdrf_topic","embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternorthwest\/wp-json\/wp\/v2\/topics?post=9791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}